Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Reaffirmed by Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Amicus Therapeutics (NASDAQ:FOLD) in a research note published on Friday, Benzinga reports. They currently have a $20.00 price target on the biopharmaceutical company’s stock.

A number of other research firms also recently commented on FOLD. JPMorgan Chase & Co. reduced their target price on Amicus Therapeutics from $17.00 to $16.00 and set an overweight rating on the stock in a report on Friday, August 16th. Jefferies Financial Group began coverage on shares of Amicus Therapeutics in a report on Friday, September 6th. They issued a buy rating and a $18.00 price objective for the company. Wells Fargo & Company began coverage on shares of Amicus Therapeutics in a report on Thursday, May 30th. They set an overweight rating and a $18.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a hold rating on shares of Amicus Therapeutics in a report on Friday, August 9th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Amicus Therapeutics currently has a consensus rating of Moderate Buy and an average target price of $17.00.

Amicus Therapeutics Stock Down 0.6 %

FOLD stock opened at $11.22 on Friday. The company has a current ratio of 2.75, a quick ratio of 2.26 and a debt-to-equity ratio of 2.93. The firm has a 50 day simple moving average of $11.05 and a 200-day simple moving average of $10.69. The company has a market capitalization of $3.32 billion, a P/E ratio of -22.90 and a beta of 0.69. Amicus Therapeutics has a twelve month low of $9.02 and a twelve month high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05). The company had revenue of $126.67 million during the quarter, compared to analyst estimates of $121.21 million. Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The firm’s revenue for the quarter was up 34.0% compared to the same quarter last year. During the same period last year, the business earned ($0.15) EPS. On average, equities research analysts predict that Amicus Therapeutics will post -0.08 earnings per share for the current fiscal year.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $11.71, for a total transaction of $87,825.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $10,382,718.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total value of $87,825.00. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $10,382,718.34. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Bradley L. Campbell sold 6,100 shares of the business’s stock in a transaction on Friday, July 5th. The stock was sold at an average price of $10.00, for a total value of $61,000.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $8,866,540. The disclosure for this sale can be found here. Over the last quarter, insiders sold 21,100 shares of company stock worth $226,375. Insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of FOLD. Vanguard Group Inc. lifted its position in Amicus Therapeutics by 5.0% in the fourth quarter. Vanguard Group Inc. now owns 28,492,486 shares of the biopharmaceutical company’s stock worth $404,308,000 after purchasing an additional 1,360,613 shares during the period. Norges Bank acquired a new stake in shares of Amicus Therapeutics in the fourth quarter valued at $35,915,000. Assenagon Asset Management S.A. bought a new position in Amicus Therapeutics during the second quarter valued at about $8,386,000. UBS Group AG grew its holdings in Amicus Therapeutics by 58.1% during the fourth quarter. UBS Group AG now owns 824,708 shares of the biopharmaceutical company’s stock worth $11,703,000 after acquiring an additional 303,038 shares during the period. Finally, M&G Plc raised its position in Amicus Therapeutics by 12.4% in the second quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company’s stock worth $7,485,000 after acquiring an additional 82,728 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.